Hims & Hers is facing battles on multiple fronts as it seeks to maintain its lucrative business in copycat weight loss drugs. Federal regulators are seeking to rein in the online telemedicine platform, which for years has been selling a non-Food and Drug Administration (FDA) approved version of GLP-1 medication semaglutide even though it is […]
Comments are closed.